KALA BIO (KALA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 Sep, 2026Executive summary
The annual meeting will be held virtually on November 3, 2026, with voting available online, by phone, or by mail.
Stockholders will vote on director elections, executive compensation, auditor ratification, a reverse stock split, and potential adjournment.
Proxy materials are distributed primarily via Internet to reduce costs and environmental impact.
Voting matters and shareholder proposals
Election of two Class III directors, Yonatan Colman and Brendan Purdy, for terms ending in 2029.
Advisory vote on executive compensation (say-on-pay).
Ratification of HTL International, LLC as independent auditor for 2026.
Approval of a reverse stock split at a ratio between 1-for-2 and 1-for-300.
Approval to adjourn the meeting if necessary to solicit additional proxies or in the absence of a quorum.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of five members divided into three staggered classes.
Avi Minkowitz serves as CEO, CFO, and Chair; Chaim Berger is Lead Independent Director.
Majority of directors are independent per Nasdaq rules.
Board committees include audit, compensation, and nominating/governance, all with independent members.
Director nomination process emphasizes integrity, business acumen, and diversity of skills and backgrounds.
Latest events from KALA BIO
- Stockholders will vote on director elections, executive pay, auditor ratification, and a reverse stock split.KALA
Proxy filing - Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable.KALA
Q2 2026 - Pivoting to AI platform services for biotech, with $350M shelf registration and recent restructuring.KALA
Registration filing - Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions.KALA
Q1 2026 - Pivoting to AI for biotech, offering $350M in securities amid high strategic and execution risk.KALA
Registration filing - Transitioned to AI platform development after clinical failure, with narrowed losses and ongoing liquidity risks.KALA
Q4 2025 - Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALA
Registration Filing - All proposals, including director elections and share increase, passed unanimously.KALA
AGM 2026 - KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALA
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference